In metastatic, immunologically ‘cold’ non-small cell lung cancer, the combination of radiation therapy and immune checkpoint inhibition (ICI) demonstrates heightened anti-tumor immune responses at non-irradiated sites and improved clinical responses compared with ICI alone. Radio-immunotherapy holds promise for patients with ICI-refractory lung cancer.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Grant, M. J., Herbst, R. S. & Goldberg, S. B. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat. Rev. Clin. Oncol. 18, 625–644 (2021). This review article is on the state of the art of immunotherapy regimens for patients with metastatic NSCLC.
Formenti, S. C. et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat. Med. 24, 1845–1851 (2018). This study reports that combined radiation therapy and ICI induced a systemic anti-tumor immune response in chemotherapy-refractory metastatic NSCLC.
Galluzzi, L. et al. Emerging evidence for adapting radiotherapy to immunotherapy. Nat. Rev. Clin. Oncol. 20, 543–557 (2023). This review article discusses the evidence in support of radiotherapy-driven immunomodulation and clinical efficacy.
Theelen, W. S. M. E. et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non–small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 5, 1276–1282 (2019). This paper presents the clinical efficacy results of the randomized controlled PEMBRO-RT trial in patients with metastatic NSCLC.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Huang, J. et al. Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer. Nat. Cancer https://doi.org/10.1038/s43018-025-01018-w (2025).
Rights and permissions
About this article
Cite this article
Improved immune responses in lung cancer with radiotherapy and immune checkpoint inhibition. Nat Cancer 6, 1617–1618 (2025). https://doi.org/10.1038/s43018-025-01019-9
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s43018-025-01019-9